La vendita allo scoperto per Zivo Bioscience dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Zivo Bioscience. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Zivo Bioscience (OTC:ZIVO) Azioni, Report sulle vendite allo scoperto

Zivo Bioscience

Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's candidates are Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Companion Animal Food Ingredient, NDI (New Dietary Ingredient, and Skin Health.

ZIVO BIOSCIENCE INC by Zivo Bioscience, Inc.

Zivo Bioscience Inc

Zivo Bioscience Inc Warrants (29/04/2026)

WIIM

CRSR

Corsair Gaming shares are trading lower after the company reported mixed Q1 financial results.

In a world increasingly defined by digital assets, borderless banking, and decentralized infrastructure, there is one foundational piece still lagging behind: identity. Who you are, how you prove it, and who controls that information are questions that financial institutions, regulators, and individuals are all racing to answer.
By 2030, the solution may come from an emerging concept already gaining traction in tech circles: self-sovereign identity (SSI). And if you&#8217;re paying attention to the future of finance, it&#8217;s time to understand why this quiet revolution in identity could reshape everything from KYC to asset access.
<h3 class="wp-block-heading">What Is Self-Sovereign Identity (SSI)?</h3>
Self-sovereign identity is a decentralized model that allows individuals to own, manage, and share their digital credentials without relying on a central authority. Instead of logging into banks, brokerages, or apps using credentials stored by third parties, users carry verifiable credentials in a digital wallet they control.
Think of it as a blockchain-secured passport that works across platforms—except you decide who sees what, and when.
SSI enables:
<ul>
<li>Reusable, verified digital credentials (e.g., age, citizenship, income proof)</li>
<li>Privacy-preserving access to services (only the data required is shared)</li>
<li>Elimination of centralized databases vulnerable to hacks</li>
</ul>
<h3 class="wp-block-heading">Why Finance Needs SSI</h3>
Today, financial access is built on a patchwork of identity checks: KYC, AML, credit scoring, and jurisdictional gatekeeping. These systems are:
<ul>
<li>Costly to maintain</li>
<li>Friction-heavy for users</li>
<li>Prone to data breaches</li>
<li>Incompatible across borders</li>
</ul>
SSI fixes these problems by creating a portable, tamper-proof identity layer that can follow the user from country to country, platform to platform.
<h3 class="wp-block-heading">Real-World Applications Already Emerging</h3>
<ul>
<li>KYC Simplification: Instead of uploading documents to every exchange, wallet, or bank, users could submit a single verified credential.</li>
<li>Borderless Finance: SSI enables seamless onboarding for global DeFi platforms without sacrificing compliance.</li>
<li>Reputation Systems: Investors and lenders can assess trustworthiness through on-chain activity, verifiable income, or education records.</li>
<li>Embedded Compliance: Regulators could approve identity schemas without needing constant data collection.</li>
</ul>
<h3 class="wp-block-heading">Who&#8217;s Building It?</h3>
Several players are leading the charge:
<ul>
<li>Microsoft and ConsenSys with their ION project</li>
<li>Sovrin Foundation, focused on decentralized identity networks</li>
<li>World Economic Forum, actively shaping digital ID policy frameworks</li>
<li>European Union, integrating SSI concepts into its eIDAS 2.0 regulation</li>
</ul>
Even the private sector is catching on, with startups integrating digital ID into financial onboarding and tokenized asset platforms.
<h3 class="wp-block-heading">What Investors Should Be Watching</h3>
SSI isn&#8217;t just a technical upgrade. It&#8217;s an investment theme with implications across fintech, cybersecurity, DeFi, and Web3. Key areas to monitor:
<ul>
<li>Wallets and platforms that support verified credentials</li>
<li>SSI integration into tokenized investment platforms</li>
<li>Regulatory clarity on digital ID standards</li>
<li>Companies building identity infrastructure (e.g., verifiers, issuers, networks)</li>
</ul>
<h3 class="wp-block-heading">Final Thought: Identity Is the Next Frontier in Finance</h3>
In the age of tokenized assets, decentralized finance, and programmable money, identity is the glue that holds everything together. Without a trusted, flexible, and user-controlled way to prove who we are, the future of finance remains incomplete.
Self-sovereign identity promises a future where access to capital, credit, and opportunity isn't just efficient. It's fair, secure, and truly global.
By 2030, the winners in finance won&#8217;t just be those who built the best portfolios. They'll be the ones who built trust without borders.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

Opinion

Trading Ideas

Why Self-Sovereign ID Will Reshape Finance By 2030

Wedbush analyst Daniel Ives maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Outperform and lowers the price target from $160 to $145.

News

Price Target

Analyst Ratings

QLYS

Wedbush Maintains Outperform on Qualys, Lowers Price Target to $145

CrowdStrike Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading lower Wednesday after the cybersecurity company announced a new strategic initiatives, including <a href="https://www.benzinga.com/quote/CRWD/earnings">a workforce reduction</a>.
What Happened: CrowdStrike said in a filing Wednesday morning that it adopted a strategic plan to make operations more efficient. The plan includes cutting approximately 500 roles, or 5% of the company&#8217;s global workforce in an effort to operate with discipline as it continues to target scaling up to $10 billion in annual recurring revenue. 
CrowdStrike expects to incur approximately $36 million to $53 million in charges related to the plan. $7 million of those charges are expected to be recognized in the first quarter. The actions are expected to be substantially complete by the end of the second quarter.
CrowdStrike said it expects first-quarter financial results to be in line with or above guidance provided in its <a href="https://www.benzinga.com/news/earnings/25/03/44127302/crowdstrike-q4-earnings-revenue-beat-eps-beat-strong-momentum-shares-slide-on-soft-guidance">fourth-quarter earnings release</a>. CrowdStrike previously guided for first-quarter revenue of $1.1 billion to $1.106 billion, and first-quarter adjusted earnings of 64 cents to 66 cents per share. 
CrowdStrike also reaffirmed its full-year guidance of $4.74 billion to $4.81 billion in revenue and adjusted earnings of $3.33 to $3.45 per share.
CrowdStrike is due to report first-quarter financial results after the market close on June 3. 
CRWD Price Action: <a href="http://benzinga.com/quote/crwd">CrowdStrike shares</a> were down 3.81% at $426.31 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/05/45229107/paul-tudor-jones-warns-ai-could-kill-50-of-humanity-without-proper-oversight-were-creating-something-thats-really-dangerous">Paul Tudor Jones Warns AI Could &#8216;Kill 50% Of Humanity&#8217; Without Proper Oversight: &#8216;We&#8217;re Creating Something That&#8217;s Really Dangerous&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Peter+Vandenbelt">VDB Photos</a>/Shutterstock.

Earnings

Guidance

Movers

CRWD

CrowdStrike Stock Is Sliding Wednesday: What's Going On?

Wedbush analyst Daniel Ives reiterates IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Outperform and maintains $300 price target.

Reiteration

Wedbush Reiterates Outperform on IBM, Maintains $300 Price Target

L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) has outperformed the market over the past 20 years by 2.41% on an annualized basis producing an average annual return of 10.57%. Currently, L3Harris Technologies has a market capitalization of $40.79 billion. 
Buying $1000 In LHX: If an investor had bought $1000 of LHX stock 20 years ago, it would be worth $7,462.04 today based on a price of $218.19 for LHX at the time of writing.
<h3>L3Harris Technologies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746634536_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In L3Harris Technologies 20 Years Ago Would Be Worth Today

MBIA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBI#NYSE">MBI</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-08. Here's what investors need to know before the announcement.
Analysts estimate that MBIA will report an earnings per share (EPS) of $-0.07. 
Investors in MBIA are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.37, which was followed by a 13.53% drop in the share price the next day.
Here's a look at MBIA's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.33</td>
<td>-0.3</td>
<td>-0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.48</td>
<td>0</td>
<td>-2.9</td>
<td>-0.52</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-14.000000000000002%</td>
<td>7.000000000000001%</td>
<td>-8.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746634477_0.png" alt="eps graph" />
<h3>Tracking MBIA's Stock Performance</h3>
Shares of MBIA were trading at $4.64 as of May 06. Over the last 52-week period, shares are down 30.21%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/MBI/earnings">To track all earnings releases for MBIA visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of MBIA's Earnings

In today&#8217;s digital-first economy, the financial sector is undergoing a seismic shift. From personal banking apps to complex trading platforms, financial services are increasingly powered by technology. At the heart of this transformation lies custom fintech software—tailor-made digital solutions designed to meet the specific needs of businesses operating in finance. As a business leader, understanding how and when to invest in such technology is crucial not just for staying competitive, but for ensuring long-term growth and innovation.
This strategic guide aims to demystify the process of investing in custom fintech software. It explores why businesses are moving away from off-the-shelf solutions, the key benefits and risks, how to select the right development partner, and what returns to expect.
<h3 class="wp-block-heading">The Case for Custom Fintech Software</h3>
While generic fintech tools can offer fast implementation and lower upfront costs, they often come with limitations: restricted functionality, poor integration capabilities, and limited scalability. Custom software, on the other hand, is designed around your business model, user requirements, and long-term objectives. It gives you full control over features, design, compliance, and data security.
In sectors like banking, insurance, and asset management—where security, precision, and regulation are critical—custom solutions provide the agility and specificity that standard tools can&#8217;t match.
<h3 class="wp-block-heading">Key Benefits of Custom Solutions</h3>
<h4 class="wp-block-heading">1. Competitive Differentiation</h4>
Custom fintech software allows businesses to introduce unique features, user experiences, and workflows that are hard for competitors to replicate. Whether it&#8217;s a personalized client portal or a proprietary risk assessment tool, the ability to innovate sets you apart in a crowded marketplace.
<h4 class="wp-block-heading">2. Enhanced Data Security &amp; Compliance</h4>
The financial industry operates under intense regulatory scrutiny. Custom solutions can be built to meet specific regulatory requirements (like GDPR, PCI-DSS, or SOX) right from the design phase. You also gain greater control over your data infrastructure, reducing third-party vulnerabilities.
<h4 class="wp-block-heading">3. Seamless Integration</h4>
Most financial businesses rely on a range of systems—from CRMs and ERPs to trading engines and payment gateways. Custom software ensures smooth interoperability with existing infrastructure, eliminating inefficiencies and data silos.
<h4 class="wp-block-heading">4. Scalability and Flexibility</h4>
Off-the-shelf software can be a bottleneck as your business grows. Custom applications, in contrast, are designed with your growth trajectory in mind. You can scale features, expand to new markets, or integrate emerging technologies like blockchain or AI without major overhauls.
<h3 class="wp-block-heading">Key Considerations Before Investing</h3>
<h4 class="wp-block-heading">1. Defining Clear Business Objectives</h4>
Before committing to custom development, it's vital to articulate the problem you&#8217;re solving. Are you improving internal operations? Creating a better customer experience? Meeting a new regulatory mandate? Clear goals will guide the development roadmap and ROI measurement.
<h4 class="wp-block-heading">2. Budgeting Beyond Development</h4>
Many business leaders focus on the initial development cost, overlooking post-launch needs like maintenance, updates, cybersecurity, and user training. A complete financial plan should cover the total cost of ownership over time.
<h4 class="wp-block-heading">3. Choosing the Right Tech Stack</h4>
Your choice of programming languages, frameworks, and databases will influence the software&#8217;s performance, scalability, and maintainability. Consult with experienced architects and make decisions that align with your long-term business and technology strategy.
<h4 class="wp-block-heading">4. Selecting a Development Partner</h4>
Partnering with a trustworthy and skilled software development company is one of the most critical decisions in this journey. If your business operates across Europe, for instance, choosing a software development company in France could offer the dual advantage of EU regulatory familiarity and high engineering standards.
<h3 class="wp-block-heading">Evaluating ROI and Measuring Success</h3>
Custom fintech software is a significant investment, and business leaders must measure returns beyond just revenue. Here are key performance indicators (KPIs) to track:
<ul>
<li>Operational Efficiency: Are you saving time or resources compared to your previous tools?</li>
<li>Customer Satisfaction: Is your client experience more seamless or personalized?</li>
<li>Compliance and Risk Management: Have regulatory issues decreased or become easier to manage?</li>
<li>Market Expansion: Has the software enabled entry into new markets or services?</li>
</ul>
Success also depends on user adoption, system performance, and ongoing innovation. Make sure to gather feedback and iterate quickly.
<h3 class="wp-block-heading">Risks and How to Mitigate Them</h3>
<h4 class="wp-block-heading">1. Scope Creep</h4>
Without a clear scope, development projects can spiral in time and cost. Establish a minimum viable product (MVP) with essential features and follow agile practices to add features iteratively.
<h4 class="wp-block-heading">2. Vendor Dependence</h4>
Custom solutions often tie you to a particular development team. Ensure proper documentation, code ownership rights, and consider source code escrow agreements to protect your business.
<h4 class="wp-block-heading">3. Compliance Gaps</h4>
Working with teams unfamiliar with financial regulations can lead to costly mistakes. Always vet your developers&#8217; experience with industry-specific compliance and certifications.
<h4 class="wp-block-heading">4. Cybersecurity Threats</h4>
Custom doesn't mean immune. Ensure security is built into the development lifecycle with threat modeling, penetration testing, and regular audits.
<h3 class="wp-block-heading">Real-World Use Cases</h3>
<ul>
<li>Wealth Management Firms: Built custom platforms for clients to view portfolios, receive financial advice, and execute trades.</li>
<li>Insurtech Startups: Developed underwriting engines that automate policy issuance based on real-time risk analysis.</li>
<li>Retail Banks: Created mobile apps with AI-powered customer service and personalized financial planning tools.</li>
<li>Crypto Exchanges: Built scalable trading engines with custom compliance modules for different jurisdictions.</li>
</ul>
<h3 class="wp-block-heading">Final Thoughts</h3>
Investing in custom fintech software is not merely a technical decision; it&#8217;s a strategic business move. It allows organizations to respond to market needs faster, offer differentiated value, and maintain compliance in an ever-evolving regulatory landscape.
However, success requires more than capital. It demands vision, planning, and the right partners. For business leaders willing to invest the time and resources, custom fintech solutions can offer an unmatched edge in today&#8217;s technology-driven financial ecosystem.
Whether you&#8217;re a startup entering the fintech space or an established institution looking to modernize, the opportunity to innovate through custom software has never been greater. The key is to approach it strategically—as an investment in your company's future agility, security, and growth.

Tech

General

Investing in Custom Fintech Software: A Strategic Guide for Business Leaders

Wedbush analyst Daniel Ives maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Outperform and lowers the price target from $155 to $140.

DDOG

Wedbush Maintains Outperform on Datadog, Lowers Price Target to $140

Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) stock is trading higher on Wednesday after the company&#8217;s first-quarter 2025 financial results. <a href="https://www.benzinga.com/pressreleases/25/05/g45248070/teva-reports-ninth-consecutive-quarter-of-growth-in-q1-2025-with-key-innovative-medicines-growing-" target="_blank" rel="noreferrer noopener">Here are the details</a>.
Teva reported revenue of $3.89 billion, up 5% year-over-year, missing analyst estimates of $4.00 billion, according to&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The increase was driven by higher revenues from Austedo in the U.S. segment. Austedo&#8217;s worldwide revenues were $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024.
<ul>
<li>U.S. Austedo revenues increased by 40% to $396 million, mainly due to volume growth, including the approval of Austedo XR, a once-daily pill, in May 2024.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?</a>
Ajovy&#8217;s global revenues were $139 million in Q1 2025, an increase of 26% in local currency terms compared to Q1 2024.
<ul>
<li>US Ajovy&nbsp;revenues were $53 million, an increase of 18% compared to the first quarter of 2024, mainly due to volume growth.</li>
<li>Uzedy&#8217;s global revenues are $39 million in Q1 2025.</li>
<li>The generics business grew across all regions—it increased by 5% in the U.S., 1% in Europe, and 2% in International Markets, all in local currency terms, compared to Q1 2024.</li>
</ul>
The company reported first-quarter adjusted earnings of 52 cents per share, beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimates of 48 cents per share</a>.
Gross profit margin&nbsp;was 48.2% in the first quarter of 2025, compared to 46.4% a year ago, and adjusted gross profit margin&nbsp;was 52.8% compared to 51.4% in the first quarter of 2024.
<ul>
<li>The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products, primarily driven by higher revenues from Austedo, partially offset by a negative impact from foreign exchange rate movements, including hedging effects.</li>
</ul>
Richard Francis, Teva&#8217;s president and CEO, said, &#8220;Now entering the Acceleration Phase of our Pivot to Growth Strategy, we have a clear roadmap to continue Teva&#8217;s transformation into a leading biopharmaceutical company with an expected 30% operating margin, and today have announced ~$700 million net savings by 2027. We&#8217;re accelerating innovative growth and strengthening our generics business, while streamlining our operations, sharpening our business, and optimizing processes. With these results, we are revising our 2025 outlook and reaffirming our 2027 targets.&#8221;
Guidance: Teva Pharmaceutical raises fiscal 2025 adjusted earnings per share from $2.35-$2.65 to $2.45-$2.65 versus the consensus of $2.55.
The generics player narrows 2025 sales guidance from $16.8 billion-$17.4 billion to $16.8 billion-$17.2 billion compared to the consensus of $17.24 billion.
The company said the outlook is based on the existing tariff and trade environment, and does not reflect any policy shifts, including pharmaceutical sector tariffs, that could impact business.
The company increased the Austedo 2025 sales outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.
Teva reaffirmed sales forecasts of $600 million for Ajovy, about $160 million for Uzedy, and approximately $370 million for Copaxone.
Teva also raised operating income guidance from&nbsp;$4.1 billion-$4.6 billion to $4.3 billion-$4.6 billion, with adjusted EBITDA of $4.7 billion-$5.0 billion from $4.5 billion-$5.0 billion.
Price Action: TEVA stock is up 8.2% at $17.48 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45254006/bunge-q1-eps-beats-expectations-cites-tariff-driven-demand-shifts-as-tailwind" target="_blank" rel="noreferrer noopener">Bunge Q1 EPS Beats Expectations, CEO Credits &#8216;Tariff-Related Timing Shifts&#8217; As Tailwind</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

TEVA

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

U stock has given up its prior gain. Unity Software shares were trading higher following better-than-expected Q1 financial results.

Wedbush analyst Matt Bryson maintains Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Neutral and lowers the price target from $40 to $30.

SMCI

Wedbush Maintains Neutral on Super Micro Computer, Lowers Price Target to $30

Shares of Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) dropped 11.4% to $54.25 on Wednesday following a late Tuesday press release announcing the <a href="https://www.benzinga.com/pressreleases/25/05/n45235781/marvell-to-host-webinar-on-the-future-of-custom-silicon-technology-for-ai-infrastructure-postpones">postponement</a> of its Investor Day and updates on its AI strategy.
What To Know: The semiconductor company cited ongoing macroeconomic uncertainty as the reason for delaying the June 2025 event to an unspecified date in 2026.
To maintain investor engagement, Marvell said the company will instead <a href="https://www.benzinga.com/pressreleases/25/05/n45235781/marvell-to-host-webinar-on-the-future-of-custom-silicon-technology-for-ai-infrastructure-postpones">host a webinar on June 17</a> focused on the future of custom silicon for AI infrastructure. The webinar will coincide with the company's annual senior technical leadership conference. 
Executives plan to discuss advances in Marvell's AI technology platform and the growing demand for custom silicon solutions.
What Else: CEO Matt Murphy highlighted continued momentum in the company's custom AI silicon business, noting the webinar as an opportunity to update investors on developments since last year's AI Day.
Despite the event delay, Marvell reaffirmed the midpoint of its fiscal first-quarter 2026 revenue outlook at $1.875 billion and narrowed its guidance range to +/-2%, from the previous +/-5%, signaling confidence in near-term performance.
Read Also: <a href="https://www.benzinga.com/news/25/05/45254436/oklo-stock-slides-following-tuesdays-surge-whats-going-on">Oklo Stock Slides Following Tuesday&#8217;s Surge: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy MRVL Stock</h2>
By now you're likely curious about how to participate in the market for Marvell Technology &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Marvell Technology, which is trading at $54.25 as of publishing time, $100 would buy you 1.84 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MRVL has a 52-week high of $127.48 and a 52-week low of $47.08.

MRVL

Marvell Technology (MRVL) Shares Slide 10% After Postponing Investor Day

Electric vehicle stocks Rivian Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) are in the spotlight Wednesday after the pair of EV makers reported <a href="https://www.benzinga.com/news/earnings/25/05/45236756/rivian-q1-earnings-double-beat-record-gross-profit-delivery-estimates-lowered-on-tariff-concerns">first-quarter financial results</a>.
RIVN Q1 Earnings: Rivian reported first-quarter revenue of $1.24 billion, beating analyst <a href="http://benzinga.com/quote/rivn/earnings">estimates</a> of $1 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported a first-quarter loss of 48 cents per share, beating estimates for a loss of 87 cents per share. 
Rivian said it produced 14,611 vehicles in the first quarter and delivered 8,640 vehicles. The company expects to deliver 40,000 to 46,000 vehicles in 2025, down from prior guidance of 46,000 to 51,000. Rivian also noted that its R2 platform is set to begin production in the first half of 2026.
&#8220;This quarter we hit our second consecutive gross profit and our highest gross profit to date at $206 million. We have continued to make significant progress on R2, including vehicle validation builds underway and our Normal, Illinois manufacturing facility expansion on track,&#8221; said RJ Scaringe, founder and CEO of Rivian.
Following the print, Needham and Wells Fargo analysts <a href="https://www.benzinga.com/analyst-stock-ratings">lowered price targets</a> to $16 and $13, respectively. Cantor Fitzgerald analysts maintained a $15 target.
Check This Out: <a href="https://www.benzinga.com/25/05/45245613/rivian-ceo-rj-scaringe-says-donald-trumps-tariffs-could-increase-costs-by-a-couple-of-thousand-as-company-slashes-delivery-projections">Rivian CEO RJ Scaringe Says Donald Trump&#8217;s Tariffs Could Increase Costs By &#8216;A Couple Of Thousand,&#8217; Slashes Delivery Projections</a>
LCID Q1 Earnings: Lucid reported first-quarter revenue of $235.05 million, missing <a href="https://www.benzinga.com/quote/LCID/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a> of $250 million. The company reported a first-quarter loss of 20 cents per share, beating analyst estimates for a loss of 23 cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Lucid said it produced 2,212 vehicles in the first quarter and delivered 3,109 vehicles. The production number doesn't include more than 600 vehicles in transit to Saudi Arabia. The company continues to expect to produce approximately 20,000 vehicles in 2025.
"Lucid Gravity is beginning to arrive in more customers' driveways and at our studios, and combined with our progress toward future initiatives, our company is well-positioned for future success,&#8221; said Marc Winterhoff, interim CEO of Lucid.
Following the print, Cantor Fitzgerald analysts reiterated a Neutral rating with a price target of $3.
RIVN, LCID Price Action: At the time of publication, Rivian shares were down 0.26% at $13.54 and Lucid shares were up 1.07% at $2.35, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45244989/lucid-group-q1-2025-earnings-tesla-rival-announces-58-increase-in-deliveries-plans-to-introduce-a-mid-size-platform-in-2026">Tesla-Rival Lucid Announces 58% Increase In Deliveries, Plans To Introduce Mid-Size Platform In 2026</a></li>
</ul>
Photos: courtesy of Rivian &amp; Lucid.

LCID

RIVN

What's Going On With EV Stocks Rivian, Lucid On Wednesday?

Wedbush analyst Matt Bryson maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Outperform and raises the price target from $115 to $120.

Wedbush Maintains Outperform on Advanced Micro Devices, Raises Price Target to $120

ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate ALX Oncology Holdings to report an earnings per share (EPS) of $-0.34.
Investors in ALX Oncology Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 19.08% drop in the share price on the subsequent day.
Here's a look at ALX Oncology Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.39</td>
<td>-0.78</td>
<td>-0.77</td>
<td>-0.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.44</td>
<td>-0.45</td>
<td>-0.62</td>
<td>-0.57</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-19.0%</td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746634197_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of ALX Oncology Holdings were trading at $0.5037 as of May 06. Over the last 52-week period, shares are down 97.14%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ALXO/earnings">To track all earnings releases for ALX Oncology Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALXO

What's Next: ALX Oncology Holdings's Earnings Preview

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Nektar Therapeutics to report an earnings per share (EPS) of $-0.18.
The market awaits Nektar Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 0.56% drop in the share price the following trading session.
Here's a look at Nektar Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.19</td>
<td>-0.21</td>
<td>-0.20</td>
<td>-0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.15</td>
<td>-0.18</td>
<td>-0.25</td>
<td>-0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-8.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746634186_0.png" alt="eps graph" />
<h3>Market Performance of Nektar Therapeutics's Stock</h3>
Shares of Nektar Therapeutics were trading at $0.642 as of May 06. Over the last 52-week period, shares are down 61.72%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Insights on Nektar Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Nektar Therapeutics.
A total of 4 analyst ratings have been received for Nektar Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $5.25, suggesting a potential 717.76% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of scPharmaceuticals and Aclaris Therapeutics, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for scPharmaceuticals, with an average 1-year price target of $16.5, suggesting a potential 2470.09% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Aclaris Therapeutics, with an average 1-year price target of $15.0, suggesting a potential 2236.45% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for scPharmaceuticals and Aclaris Therapeutics, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nektar Therapeutics</td>
<td>Buy</td>
<td>22.15%</td>
<td>$21.20M</td>
<td>13.25%</td>
</tr>
<tr>
<td>scPharmaceuticals</td>
<td>Buy</td>
<td>99.31%</td>
<td>$8.19M</td>
<td>-85.60%</td>
</tr>
<tr>
<td>Aclaris Therapeutics</td>
<td>Outperform</td>
<td>-47.58%</td>
<td>$-90K</td>
<td>-67.59%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Nektar Therapeutics ranks highest in gross profit among its peers. It is in the middle for consensus rating and revenue growth. However, it has the highest return on equity compared to its peers.
<h3>Delving into Nektar Therapeutics's Background</h3>
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
<h3>Unraveling the Financial Story of Nektar Therapeutics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Nektar Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 22.15%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Nektar Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Nektar Therapeutics's ROE excels beyond industry benchmarks, reaching 13.25%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Nektar Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.37% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Nektar Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.69.
<a href="https://www.benzinga.com/quote/NKTR/earnings">To track all earnings releases for Nektar Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NKTR

Nektar Therapeutics's Earnings: A Preview

Keefe, Bruyette &amp; Woods analyst Ryan Tomasello maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Market Perform and lowers the price target from $80 to $76.

Keefe, Bruyette & Woods Maintains Market Perform on Zillow Gr, Lowers Price Target to $76

<a href="https://news.bloomberglaw.com/antitrust/us-appeals-court-affirms-microsoft-activision-merger?context=search&amp;index=0">https://news.bloomberglaw.com/antitrust/us-appeals-court-affirms-microsoft-activision-merger?context=search&amp;index=0</a>

MSFT

'US Appeals Court Affirms Microsoft-Activision Merger'- Bloomberg Law

Keefe, Bruyette &amp; Woods analyst Bose George maintains UWM Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) with a Outperform and lowers the price target from $7.5 to $6.5.

Comments

Zivo Bioscience

Vendite allo scoperto

Zivo Bioscience (OTC:ZIVO) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO